Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks

OBJECTIVE: We recently reported that after 26 weeks, exenatide once weekly (EQW) resulted in superior A1C reduction, reduced hypoglycemia, and progressive weight loss compared with daily insulin glargine (IG) in patients with type 2 diabetes who were taking metformin alone or with sulfonylurea. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Diamant, Michaela, Van Gaal, Luc, Stranks, Stephen, Guerci, Bruno, MacConell, Leigh, Haber, Harry, Scism-Bacon, Jamie, Trautmann, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308312/
https://www.ncbi.nlm.nih.gov/pubmed/22357185
http://dx.doi.org/10.2337/dc11-1233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308312/
https://www.ncbi.nlm.nih.gov/pubmed/22357185
http://dx.doi.org/10.2337/dc11-1233

Ejemplares similares